These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24252289)

  • 1. Additive effect of the metabolic syndrome score to the conventional CHADS₂ score for the thromboembolic risk stratification of patients with atrial fibrillation.
    Tsai CT; Chang SH; Chang SN; Hwang JJ; Wu CK; Wang YC; Tseng CD; Yeh HM; Lai LP; Chiang FT; Lin JL
    Heart Rhythm; 2014 Mar; 11(3):352-7. PubMed ID: 24252289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between CHADS2 and CHA2 DS2 -VASc score in a stroke cohort with atrial fibrillation.
    Giralt-Steinhauer E; Cuadrado-Godia E; Ois A; Jiménez-Conde J; Rodríguez-Campello Á; Soriano C; Roquer J
    Eur J Neurol; 2013 Apr; 20(4):623-8. PubMed ID: 22834861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
    Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
    JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.
    Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Prostran MS; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):319-26. PubMed ID: 22319004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
    Banerjee A; Fauchier L; Vourc'h P; Andres CR; Taillandier S; Halimi JM; Lip GY
    J Am Coll Cardiol; 2013 May; 61(20):2079-87. PubMed ID: 23524209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. R2CHADS2 score and thromboembolic events after catheter ablation of atrial fibrillation in comparison with the CHA2DS2-VASc score.
    Chao TF; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Hsieh MH; Chen SA
    Can J Cardiol; 2014 Apr; 30(4):405-12. PubMed ID: 24582725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal dysfunction and the risk of thromboembolic events in patients with atrial fibrillation after catheter ablation--the potential role beyond the CHA₂DS₂-VASc score.
    Chao TF; Tsao HM; Ambrose K; Lin YJ; Lin WS; Chang SL; Lo LW; Hu YF; Tuan TC; Suenari K; Li CH; Hartono B; Chang HY; Chung FP; Hanafy DA; Lin WY; Chen SA
    Heart Rhythm; 2012 Nov; 9(11):1755-60. PubMed ID: 22760084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of CHADS2 and CHA2DS2-VASc scores with transesophageal echocardiography risk factors for thromboembolism in a multiethnic United States population with nonvalvular atrial fibrillation.
    Willens HJ; Gómez-Marín O; Nelson K; DeNicco A; Moscucci M
    J Am Soc Echocardiogr; 2013 Feb; 26(2):175-84. PubMed ID: 23253435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolic risk evaluation in patients with atrial fibrillation using a modified CHADS(2) scoring system.
    Cha MJ; Oh GC; Hahn S; Choi EK; Oh S
    J Cardiovasc Electrophysiol; 2012 Feb; 23(2):155-62. PubMed ID: 21955174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events.
    Botto GL; Padeletti L; Santini M; Capucci A; Gulizia M; Zolezzi F; Favale S; Molon G; Ricci R; Biffi M; Russo G; Vimercati M; Corbucci G; Boriani G
    J Cardiovasc Electrophysiol; 2009 Mar; 20(3):241-8. PubMed ID: 19175849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of CHADS2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion (from the ACUTE Trial Substudy).
    Yarmohammadi H; Varr BC; Puwanant S; Lieber E; Williams SJ; Klostermann T; Jasper SE; Whitman C; Klein AL
    Am J Cardiol; 2012 Jul; 110(2):222-6. PubMed ID: 22503581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2 DS2 -VASc scores.
    Cha MJ; Kim YD; Nam HS; Kim J; Lee DH; Heo JH
    Eur J Neurol; 2012 Mar; 19(3):473-9. PubMed ID: 21972975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can thromboembolic risk be associated with erectile dysfunction in atrial fibrillation patients?
    Szymański FM; Filipiak KJ; Płatek AE; Kotkowski M; Opolski G
    Cardiol J; 2015; 22(4):446-52. PubMed ID: 25733318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible refinement of clinical thromboembolism assessment in patients with atrial fibrillation using echocardiographic parameters.
    Providência R; Botelho A; Trigo J; Quintal N; Nascimento J; Mota P; Leitão-Marques A
    Europace; 2012 Jan; 14(1):36-45. PubMed ID: 21868410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
    Friberg L; Rosenqvist M; Lip GY
    Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation.
    Chao TF; Lin YJ; Tsao HM; Tsai CF; Lin WS; Chang SL; Lo LW; Hu YF; Tuan TC; Suenari K; Li CH; Hartono B; Chang HY; Ambrose K; Wu TJ; Chen SA
    J Am Coll Cardiol; 2011 Nov; 58(23):2380-5. PubMed ID: 22115643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
    J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of new criteria for anticoagulant treatment in atrial fibrillation.
    Rodríguez-Mañero M; Cordero A; Bertomeu-González V; Moreno-Arribas J; Bertomeu-Martínez V; Mazón P; Fácila L; Cosín J; Lekuona I; Galve E; González-Juanatey JR
    Rev Esp Cardiol; 2011 Aug; 64(8):649-53. PubMed ID: 21652133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroke prediction using mean platelet volume in patients with atrial fibrillation.
    Ha SI; Choi DH; Ki YJ; Yang JS; Park G; Chung JW; Koh YY; Chang KS; Hong SP
    Platelets; 2011; 22(6):408-14. PubMed ID: 21599611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of the CHADS2 and CHA2DS2-VASc scores in post-myocardial infarction patients: Risk of new occurrence of atrial fibrillation and ischemic stroke.
    Lau KK; Chan PH; Yiu KH; Chan YH; Liu S; Chan KH; Yeung CY; Li SW; Tse HF; Siu CW
    Cardiol J; 2014; 21(5):474-83. PubMed ID: 24846512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.